LOADING
Comparing Johnson & Johnson (JNJ) and AbbVie Inc (ABBV), both in the Health Care sector. This side-by-side analysis covers price, valuation multiples, profitability, growth, dividends, and risk metrics to help investors evaluate these two stocks.
| Metric | JNJ | ABBV |
|---|---|---|
| Price | $243.04 | $208.84 |
| Change Today | -0.44% | -2.86% |
| Market Cap | $585.7B | $369.4B |
| P/E Ratio | 22.0 | 88.5 |
| Forward P/E | 21.1 | 14.8 |
| PEG Ratio | 1.70 | 0.51 |
| EPS | $11.03 | $2.36 |
| Revenue Growth (YoY) | 9.1% | 10.0% |
| Profit Margin | 28.5% | 6.9% |
| Return on Equity | 35.0% | 62.3% |
| Dividend Yield | 2.11% | 3.09% |
| Beta | 0.33 | 0.36 |
| 52-Week High | $251.71 | $241.12 |
| 52-Week Low | $137.67 | $159.05 |
| Volume | 6.9M | 5.2M |
Johnson & Johnson is the larger company by market capitalization. Johnson & Johnson trades at a lower P/E ratio, suggesting it may offer better value relative to earnings. AbbVie Inc offers a higher dividend yield for income investors. Johnson & Johnson has stronger profit margins. Both stocks should be evaluated in the context of your investment goals, risk tolerance, and portfolio diversification needs.